| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/18/2000 | US6015787 Cell-permeable protein inhibitors of calpain |
| 01/18/2000 | US6015786 Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| 01/18/2000 | US6015713 Transgenic fish and a method of harvesting islet cells therefrom |
| 01/18/2000 | US6015712 Antisense modulation of FADD expression |
| 01/18/2000 | US6015710 Specific nucleobase sequences; for administration to mammalian cells in vitro |
| 01/18/2000 | US6015709 Nucleic acid which encodes a transcription factor including transcription activation domains and a dna binding domain; for high-level expression of a target gene in genetically engineered cells |
| 01/18/2000 | US6015702 Nucleotide and amino acid sequences; for diagnosis, prevention and treatment of neoplastic, developmental, immune and nervous system disorders; anticarcinogenic/antitumor/ antisense agents |
| 01/18/2000 | US6015694 Method for stimulating an immune response utilizing recombinant alphavirus particles |
| 01/18/2000 | US6015693 Recombinant production of soluble TGF-β-binding endoglin polypeptides |
| 01/18/2000 | US6015692 Nucleic acid which encodes a recombinant polypeptide capable of binding cyclin-dependent kinase and extracellular-signal related kinase; for diagnosis of proliferative disorders; antiproliferative/anticarcinogenic agents |
| 01/18/2000 | US6015691 Nucleotide and amino acid sequences; for diagnosis and treatment of infections; for vaccines |
| 01/18/2000 | US6015690 DNA sequence encoding a human imidazoline receptor and method for cloning the same |
| 01/18/2000 | US6015689 Amino acid sequences of protein controlling sensitivity of fungus to fungicide; for diagnosis and treatment of mycoses |
| 01/18/2000 | US6015688 Transferrin receptor genes |
| 01/18/2000 | US6015687 Apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof |
| 01/18/2000 | US6015686 A eukaryotic promoter 5' of viral cdna which initiates within a cell the 5' to 3' synthesis of rna from complementary dna producing a vector construct which autonomously amplifies in a cell and expresses an heterologous sequence; gene therapy |
| 01/18/2000 | US6015685 Ancrod proteins, their preparation and use |
| 01/18/2000 | US6015678 Method for detection of a polynucleotide encoding protein kinase C inhibitor-homolog |
| 01/18/2000 | US6015676 Simple, specific and nontoxic method by transporting carboxylated single-stranded antisense probes in a delivery vector into cells, hybridizing to messenger rna with natural amino-groups causing covalent base pairing |
| 01/18/2000 | US6015672 Rab-specific guanine-nucleotide dissociation inhibitor |
| 01/18/2000 | US6015669 Identification of genes |
| 01/18/2000 | US6015665 Method and composition for regulating apoptosis |
| 01/18/2000 | US6015660 Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| 01/18/2000 | US6015578 Trapidil for use in the therapy of syndrome that may be influenced by immunomodulators |
| 01/18/2000 | US6015572 Glial cells with neurotropic factors for nerve damage |
| 01/18/2000 | US6015561 Antigen binding peptides (abtides) from peptide libraries |
| 01/18/2000 | US6015559 Fas antagonists |
| 01/18/2000 | US6015558 Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-α function |
| 01/18/2000 | US6015556 Cytotoxic drug therapy |
| 01/18/2000 | US6015552 Use of nerve growth factor-2 (NGF-2) /neurotrophin-3 (NT-3) to promote leukocyte proliferation |
| 01/18/2000 | US6015542 Radioimmunotherapy of lymphoma using anti-CD20 antibodies |
| 01/18/2000 | CA2142277C Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer |
| 01/18/2000 | CA2132954C Modified ciliary neurotrophic factors |
| 01/18/2000 | CA2005420C Competitive gonadoliberin antagonists |
| 01/18/2000 | CA1340877C Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology |
| 01/13/2000 | WO2000002051A1 Trifunctional reagent for conjugation to a biomolecule |
| 01/13/2000 | WO2000002050A1 Trifunctional reagent for conjugation to a biomolecule |
| 01/13/2000 | WO2000001851A1 Antisense oligonucleotides targeted to il-15 |
| 01/13/2000 | WO2000001841A2 Hyaluronic acid mimics and methods related thereto |
| 01/13/2000 | WO2000001831A2 Proteases fused with variants of streptomyces subtilisin inhibitor |
| 01/13/2000 | WO2000001825A1 HELICOBACTER ANTIGEN (η-GLUTAMYLTRANSPEPTIDASE) AND SEQUENCES ENCODING THE SAME |
| 01/13/2000 | WO2000001823A2 Flt3-l mutants and methods of use |
| 01/13/2000 | WO2000001821A2 Neurotransmission associated proteins |
| 01/13/2000 | WO2000001820A2 Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof |
| 01/13/2000 | WO2000001818A1 Human emr1-like g protein coupled receptor |
| 01/13/2000 | WO2000001817A2 Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods |
| 01/13/2000 | WO2000001815A2 Neurotrophic factors |
| 01/13/2000 | WO2000001813A2 Peptide inhibitors of androgen-independent activation of androgen receptor |
| 01/13/2000 | WO2000001811A1 Kv6.2, A VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT |
| 01/13/2000 | WO2000001805A1 Cells and animals deficient in protein kinase c epsilon |
| 01/13/2000 | WO2000001802A2 Peptide antagonists of the human urokinase receptor and method for selecting them |
| 01/13/2000 | WO2000001801A1 Ftsz multimeric proteins and their uses |
| 01/13/2000 | WO2000001732A2 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 01/13/2000 | WO2000001731A1 Fused protein with direct bond of il-6-receptor to il-6 |
| 01/13/2000 | WO2000001730A1 Peptides based on the sequence of human lactoferrin and their use |
| 01/13/2000 | WO2000001729A2 Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome |
| 01/13/2000 | WO2000001728A1 Galectin 11 |
| 01/13/2000 | WO2000001726A1 Compounds with growth hormone releasing properties |
| 01/13/2000 | WO2000001724A1 Microsporidium polar tube proteins, nucleic acids coding for said proteins and their uses |
| 01/13/2000 | WO2000001720A2 Compositions and methods for treating papillomavirus-infected cells |
| 01/13/2000 | WO2000001715A1 Novel cyclosporin with improved activity profile |
| 01/13/2000 | WO2000001714A1 Efflux pump inhibitors |
| 01/13/2000 | WO2000001713A2 Diacylglycerol acyl transferase proteins |
| 01/13/2000 | WO2000001706A1 N-terminal site selective inhibitors of human angiotensin conversion enzyme (ace) |
| 01/13/2000 | WO2000001690A1 Cinnamic acid derivatives as cell adhesion molecules |
| 01/13/2000 | WO2000001666A1 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 01/13/2000 | WO2000001440A2 Methods for treating neurological injuries and disorders |
| 01/13/2000 | WO2000001427A1 Bone cement with antimicrobial peptides |
| 01/13/2000 | WO2000001419A1 Drug complex for treatment of metastatic prostate cancer |
| 01/13/2000 | WO2000001417A1 Delivery system |
| 01/13/2000 | WO2000001415A2 Use of inhibitors of protein kinase c epsilon to treat pain |
| 01/13/2000 | WO2000001410A1 Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| 01/13/2000 | WO2000001407A1 Pharmaceutical composition comprising human apotransferrin and process for manufacturing of the composition |
| 01/13/2000 | WO2000001406A1 Medicinal utilization of heparin cofactor ii |
| 01/13/2000 | WO2000001405A1 Cartilage cell differentiation promoters |
| 01/13/2000 | WO2000001404A1 Compositions and methods for $i(in vitro) fertilization |
| 01/13/2000 | WO2000001403A1 USE OF COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WITHIN THE GROUP GnRH-ANALOGUES FOR TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD) |
| 01/13/2000 | WO2000001402A1 Antiproliferative and antiviral proteins and peptides |
| 01/13/2000 | WO2000001401A1 Compositions and methods for inhibiting inward-rectifier potassium channels |
| 01/13/2000 | WO2000001400A1 Compositions comprising endotoxin neutralizing protein and derivatives and uses thereof |
| 01/13/2000 | WO2000001376A2 Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| 01/13/2000 | WO2000001362A1 Preparations for protecting infants' skin against diaper dermatitis |
| 01/13/2000 | WO1999060125A3 Secreted proteins |
| 01/13/2000 | WO1999059628A3 Combination therapy for the treatment of tumors |
| 01/13/2000 | WO1999059617A3 Immunoregulator |
| 01/13/2000 | WO1999057241A3 Myelin basic protein peptides and uses thereof |
| 01/13/2000 | WO1999056770A3 Novel therapy for treatment of lysosomal storage disease |
| 01/13/2000 | WO1999055843A3 Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects |
| 01/13/2000 | WO1999055353A3 Protein formulations |
| 01/13/2000 | WO1999055312A3 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 01/13/2000 | WO1999053953A3 Methods and products related to metabolic interactions in disease |
| 01/13/2000 | WO1999053060A3 Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| 01/13/2000 | WO1999052936A3 Arginine peptide analogs useful as fibroblast growth factor antagonists |
| 01/13/2000 | WO1999051259A3 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| 01/13/2000 | WO1999046367A8 Methods of diagnosis and triage using cell activation measures |
| 01/13/2000 | WO1999043709A3 Melanocortin receptor antagonists and modulations of melanocortin receptor activity |
| 01/13/2000 | WO1999038501A3 Method of regulating glucose metabolism, and reagents related thereto |
| 01/13/2000 | WO1999037774A3 Differentiation-associated sequences and methods of use therefor |
| 01/13/2000 | WO1999018909A3 Interferon-gamma regulatory factors |
| 01/13/2000 | DE19920966A1 alpha-Ketoamidderivate alpha-Ketoamidderivate |